Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia 

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

CD­MO Nu­cle­us Ra­dio­Phar­ma is part­ner­ing with clin­i­cal-stage com­pa­ny Art­bio to man­u­fac­ture its ra­dio­phar­ma ther­a­py AB001, which is in Phase 1 and 2 tri­als for prostate can­cer, ac­cord­ing to a Tues­day an­nounce­ment. Nu­cle­us will make Art­bio’s lead-ra­di­o­la­beled ther­a­pies in Rochester, MN, and use Art­bio’s tech­nol­o­gy, dubbed Al­phaDi­rect, to iso­late lead from raw ma­te­ri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.